GlassScriptPhysician profile
Stephanie Ward
NPI 1518583491
$7,161.37
in general payments reported to CMS, 2019-2025
34 companies · $2,578 in 2025
The $2,578 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $928 · 2022: $1,512 · 2023: $799 · 2024: $1,343 · 2025: $2,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,720.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $645.15 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $598.58 | 2021-2025 | |
| Amgen INC. | $556.42 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $530.63 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $513.60 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $469.65 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $443.23 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $406.74 | 2021-2025 | Wainua, Farxiga |
| Preventric Diagnostics, INC. | $370.22 | 2022 | |
| Boston Scientific Corporation | $367.50 | 2023-2025 | Watchman Flx, Watchman Access System |
| Bridgebio Pharma, INC. | $345.11 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $340.13 | 2022-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.97 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $188.51 | 2024-2025 | |
| Scpharmaceuticals INC. | $156.36 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $150.97 | 2021-2025 | Onpattro, Amvuttra |
| Kestra Medical Technology Services, INC. | $139.92 | 2025 | Assure Wcd |
| Novo Nordisk INC | $135.01 | 2024-2025 | Wegovy, Ozempic |
| Kiniksa Pharmaceuticals International, Plc | $70.90 | 2024 | Arcalyst |
| Cardiovascular Systems INC. | $59.69 | 2022 | |
| Shockwave Medical, INC | $53.32 | 2025 | |
| Cvrx, INC. | $44.56 | 2024 | Barostim Neo System |
| Heartflow, INC. | $43.17 | 2025 | |
| Vital Connect, INC | $38.98 | 2025 | Vitalpatch Rtm |
| Kiniksa Pharmaceuticals, LTD. | $31.90 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.44 | 2025 | Tryvio |
| Daiichi Sankyo INC. | $27.40 | 2024 | Injectafer |
| Abiomed | $24.18 | 2022 | |
| Lilly USA, LLC | $22.03 | 2025 | Zepbound |
| Mannkind Corporation | $19.50 | 2025 | |
| Endologix LLC | $16.54 | 2022 | |
| Chiesi USA, INC. | $15.64 | 2024 | Cleviprex, Kengreal |
| Lexicon Pharmaceuticals, INC. | $14.31 | 2024 | |
| Elutia, INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.